Multifunctional Framework Nucleic Acid Vehicle for Antibiotic Sensitization and Treatment of Methicillin-Resistant Staphylococcus aureus

Abstract

The increasing prevalence of methicillin-resistant Staphylococcus aureus (MRSA) due to antibiotic misuse necessitates novel therapeutic strategies to counter multidrug-resistant infections. Here, we introduce a self-assembling, aggregation-enhanced tetrahedral DNA nanostructure (tFNA) platform that achieves targeted drug delivery through controlled aggregation and sustained release, effectively restoring MRSA susceptibility to β-lactam antibiotics. These tetrahedral frameworks, termed tFNAs-ASOs-ceftriaxone sodium (TACs), serve as a dual-functional system that co-encapsulates antisense oligonucleotides (ASOs) targeting the mecA gene and the β-lactam antibiotic ceftriaxone sodium (Cef). Aggregation of TACs plays a pivotal role in maximizing drug retention and stability, prolonging the localized release of both ASOs and antibiotics while maintaining high bioavailability at the infection site. Characterization studies, including size distribution, zeta potential, and fluorescence quenching assays, confirm their robust aggregation stability and encapsulation efficiency, ensuring controlled drug kinetics and prolonged therapeutic effects. Upon interaction with bacterial cells, the locally concentrated TACs facilitate efficient ASO-mediated mecA silencing, thereby disrupting PBP2a expression and re-sensitizing MRSA to β-lactams. Simultaneously, the aggregated ceftriaxone sodium reservoir ensures sustained inhibition of bacterial cell wall synthesis, leading to effective bacterial clearance. In addition, TACs display potent antibiofilm activity by penetrating the biofilm matrix and delivering therapeutics directly to the embedded bacterial population, thereby overcoming the diffusion barriers. In vivo, TACs exhibit superior therapeutic efficacy in an MRSA-induced pneumonia mouse model, significantly improving survival rates, reducing bacterial burden, and mitigating lung tissue damage. These findings highlight the transformative potential of tFNAs as an intelligent drug aggregation and release system, offering a novel paradigm for optimizing antibiotic therapy against multidrug-resistant pathogens.

Keywords

antibiotic resistance / antisense oligonucleotides / DNA aggregates / framework nucleic acids / methicillin-resistant Staphylococcus aureus

References

[1] S. Y. C. Tong, J. S. Davis, E. Eichenberger, T. L. Holland, and V. G. Fowler, “Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management,” Clinical Microbiology Reviews 28, no. 3 (2015): 603-661.

[2] A. S. Lee, H. De Lencastre, J. Garau, et al., “Methicillin-Resistant Staphylococcus aureus,” Nature Reviews Disease Primers 4 (2018): 18033.

[3] H. F. Chambers and F. R. Deleo, “Waves of Resistance: Staphylococcus aureus in the Antibiotic Era,” Nature Reviews Microbiology 7, no. 9 (2009): 629-641.

[4] G. W. Coombs, S. Pang, D. A. Daley, Y. T. Lee, S. Abraham, and M. Leroi, “Severe Disease Caused by Community-Associated MRSA ST398 Type V, Australia, 2017,” Emerging Infectious Diseases 25, no. 1 (2019): 190-192.

[5] G. Y. C. Cheung, J. S. Bae, and M. Otto, “Pathogenicity and Virulence of Staphylococcus aureus,” Virulence 12, no. 1 (2021): 547-569.

[6] Y. Sun, S. Li, Y. Zhang, et al., “Tetrahedral Framework Nucleic Acids Loading Ampicillin Improve the Drug Susceptibility Against Methicillin-Resistant Staphylococcus aureus,” ACS Applied Materials & Interfaces 12, no. 33 (2020): 36957-36966.

[7] Y. Sun, X. Chen, S. Shi, et al., “Tetrahedral Framework Nucleic Acids: A Novel Strategy for Antibiotic Treating Drug-Resistant Infections,” Biomacromolecules 24, no. 2 (2023): 1052-1060.

[8] K. Zhou, C. Li, D. Chen, et al., “A Review on Nanosystems as an Effective Approach Against Infections of Staphylococcus aureus,” International Journal of Nanomedicine 13 (2018): 7333-7347.

[9] S. T. Crooke, “Molecular Mechanisms of Antisense Oligonucleotides,” Nucleic Acid Therapeutics 27, no. 2 (2017): 70-77.

[10] W. F. Lai and W. T. Wong, “Design of Polymeric Gene Carriers for Effective Intracellular Delivery,” Trends in Biotechnology 36, no. 7 (2018): 713-728.

[11] C. Zhang, Y. Ma, J. Zhang, et al., “Modification of Lipid-Based Nanoparticles: An Efficient Delivery System for Nucleic Acid-Based Immunotherapy,” Molecules 27, no. 6 (2022): 1943.

[12] L. Johnson, D. M. Gray, E. Niezabitowska, and T. O. Mcdonald, “Multi-Stimuli-Responsive Aggregation of Nanoparticles Driven by the Manipulation of Colloidal Stability,” Nanoscale 13, no. 17 (2021): 7879-7896.

[13] M. Elsabahy and K. L. Wooley, “Design of Polymeric Nanoparticles for Biomedical Delivery Applications,” Chemical Society Reviews 41, no. 7 (2012): 2545.

[14] W. Ma, Y. Zhan, Y. Zhang, C. Mao, X. Xie, and Y. Lin, “The Biological Applications of DNA Nanomaterials: Current Challenges and Future Directions,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 351.

[15] J. Wei, Y. Sun, H. Wang, et al., “Designer Cellular Spheroids With DNA Origami for Drug Screening,” Science Advances 10, no. 29 (2024): eado9880.

[16] J. Nicolas, S. Mura, D. Brambilla, N. Mackiewicz, and P. Couvreur, “Design, Functionalization Strategies and Biomedical Applications of Targeted Biodegradable/Biocompatible Polymer-Based Nanocarriers for Drug Delivery,” Chemical Society Reviews 42, no. 3 (2013): 1147-1235.

[17] L. Wang, Q. Yao, X. Guo, et al., “Targeted Delivery of CEBPA-saRNA for the Treatment of Pancreatic Ductal Adenocarcinoma by Transferrin Receptor Aptamer Decorated Tetrahedral Framework Nucleic Acid,” Journal of Nanobiotechnology 22, no. 1 (2024): 392.

[18] L. Yao, G. Zhang, Y. Wang, et al., “Development of an Inhalable DNA Tetrahedron MicroRNA Sponge,” Advanced Materials 37, no. 4 (2025): e2414336.

[19] J. Khandare, M. Calderón, N. M. Dagia, and R. Haag, “Multifunctional Dendritic Polymers in Nanomedicine: Opportunities and Challenges,” Chemical Society Reviews 41, no. 7 (2012): 2824-2848.

[20] N. Kamaly, Z. Xiao, P. M. Valencia, A. F. Radovic-Moreno, and O. C. Farokhzad, “Targeted Polymeric Therapeutic Nanoparticles: Design, Development and Clinical Translation,” Chemical Society Reviews 41, no. 7 (2012): 2971.

[21] R. Tong, L. Tang, L. Ma, C. Tu, R. Baumgartner, and J. Cheng, “Smart Chemistry in Polymeric Nanomedicine,” Chemical Society Reviews 43, no. 20 (2014): 6982-7012.

[22] Q. Hu, H. Li, L. Wang, H. Gu, and C. Fan, “DNA Nanotechnology-Enabled Drug Delivery Systems,” Chemical Reviews 119, no. 10 (2019): 6459-6506.

[23] Z. Ge, H. Gu, Q. Li, and C. Fan, “Concept and Development of Framework Nucleic Acids,” Journal of the American Chemical Society 140, no. 51 (2018): 17808-17819.

[24] S. Li, Y. Liu, T. Zhang, et al., “A Tetrahedral Framework DNA-Based Bioswitchable miRNA Inhibitor Delivery System: Application to Skin Anti-Aging,” Advanced Materials 34, no. 46 (2022): e2204287.

[25] S. Li, T. Tian, T. Zhang, Y. Lin, and X. Cai, “A Bioswitchable Delivery System for microRNA Therapeutics Based on a Tetrahedral DNA Nanostructure,” Nature Protocols 20, no. 2 (2025): 336-362.

[26] T. Zhang, T. Tian, R. Zhou, et al., “Design, Fabrication and Applications of Tetrahedral DNA Nanostructure-Based Multifunctional Complexes in Drug Delivery and Biomedical Treatment,” Nature Protocols 15, no. 8 (2020): 2728-2757.

[27] T. Zhang, T. Tian, and Y. Lin, “Functionalizing Framework Nucleic-Acid-Based Nanostructures for Biomedical Application,” Advanced Materials 34, no. 46 (2022): e2107820.

[28] P. Song, J. Shen, D. Ye, et al., “Programming Bulk Enzyme Heterojunctions for Biosensor Development With Tetrahedral DNA Framework,” Nature Communications 11, no. 1 (2020): 838.

[29] H. Dong, G. Song, D. Ma, et al., “Improved Antiviral Activity of Classical Swine Fever Virus-Targeted siRNA by Tetrahedral Framework Nucleic Acid-Enhanced Delivery,” ACS Applied Materials & Interfaces 13, no. 25 (2021): 29416-29423.

[30] C. J. Tsai, J. M. Loh, and T. Proft, “Galleria Mellonella Infection Models for the Study of Bacterial Diseases and for Antimicrobial Drug Testing,” Virulence 7, no. 3 (2016): 214-229.

[31] J. Bubeck Wardenburg and O. Schneewind, “Vaccine Protection Against Staphylococcus aureus Pneumonia,” Journal of Experimental Medicine 205, no. 2 (2008): 287-294.

[32] J. Bubeck Wardenburg, R. J. Patel, and O. Schneewind, “Surface Proteins and Exotoxins Are Required for the Pathogenesis of Staphylococcus aureus Pneumonia,” Infection and Immunity 75, no. 2 (2007): 1040-1044.

[33] S. Jing, L. Wang, T. Wang, et al., “Myricetin Protects Mice Against MRSA-Related Lethal Pneumonia by Targeting ClpP,” Biochemical Pharmacology 192 (2021): 114753.

[34] N. Ahlskog, N. Svrzikapa, R. Abuhamdah, et al., “uORF-Targeting Steric Block Antisense Oligonucleotides Do Not Reproducibly Increase RNASEH1 Expression,” Molecular Therapy Nucleic Acids 36, no. 1 (2025): 102406.

[35] A. Mata-Ventosa, A. Vila-Planas, A. Solsona-Pujol, et al., “RNase H-Sensitive Multifunctional ASO-Based Constructs as Promising Tools for the Treatment of Multifactorial Complex Pathologies,” Bioorganic Chemistry 150 (2024): 107595.

[36] T. C. Roberts, R. Langer, and M. J. A. Wood, “Advances in Oligonucleotide Drug Delivery,” Nature Reviews Drug Discovery 19, no. 10 (2020): 673-694.

[37] O. Khorkova and C. Wahlestedt, “Oligonucleotide Therapies for Disorders of the Nervous System,” Nature Biotechnology 35, no. 3 (2017): 249-263.

[38] J. Li, C. Fan, H. Pei, J. Shi, and Q. Huang, “Smart Drug Delivery Nanocarriers With Self-Assembled DNA Nanostructures,” Advanced Materials 25, no. 32 (2013): 4386-4396.

[39] R. L. Juliano, “The Delivery of Therapeutic Oligonucleotides,” Nucleic Acids Research 44, no. 14 (2016): 6518-6548.

[40] M. B. Abd Elhaleem, “Chemisorption and Sustained Release of Cefotaxime Between a Layered Double Hydroxide and Polyvinyl Alcohol Nanofibers for Enhanced Efficacy Against Second Degree Burn Wound Infection,” RSC Advances 10, no. 22 (2020): 13196-13214.

[41] J. Rolo, P. Worning, J. Boye Nielsen, et al., “Evidence for the Evolutionary Steps Leading to mecA-Mediated β-Lactam Resistance in Staphylococci,” PLoS Genetics 13, no. 4 (2017): e1006674.

[42] H. Lade and J. S. Kim, “Molecular determinants of β-lactam resistance in methicillin-resistant Staphylococcus aureus (MRSA): An updated review,” Antibiotics 12, no. 9 (2023): 1362.

[43] H. Hu, S. Y. Hua, X. Lin, et al., “Hybrid Biomimetic Membrane Coated Particles-Mediated Bacterial Ferroptosis for Acute MRSA Pneumonia,” ACS Nano 17, no. 12 (2023): 11692-11712.

[44] J. Yan, X. Ma, D. Liang, et al., “An Autocatalytic Multicomponent DNAzyme Nanomachine for Tumor-Specific Photothermal Therapy Sensitization in Pancreatic Cancer,” Nature Communications 14, no. 1 (2023): 6905.

[45] S. Y. Tong, J. S. Davis, E. Eichenberger, T. L. Holland, and V. G. Fowler, “Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management,” Clinical Microbiology Reviews 28, no. 3 (2015): 603-661.

[46] F. Yang, Q. Li, L. Wang, G.-J. Zhang, and C. Fan, “Framework-Nucleic-Acid-Enabled Biosensor Development,” ACS Sensors 3, no. 5 (2018): 903-919.

[47] L. Feng, J. Li, J. Sun, L. Wang, C. Fan, and J. Shen, “Recent Advances of DNA Nanostructure-Based Cell Membrane Engineering,” Advanced Healthcare Materials 10, no. 6 (2021): e2001718.

[48] Q. Hu, S. Wang, L. Wang, H. Gu, and C. Fan, “DNA Nanostructure-Based Systems for Intelligent Delivery of Therapeutic Oligonucleotides,” Advanced Healthcare Materials 7, no. 20 (2018): e1701153.

[49] T. J. Foster, “Can β-Lactam Antibiotics Be Resurrected to Combat MRSA?,” Trends in Microbiology 27, no. 1 (2019): 26-38.

RIGHTS & PERMISSIONS

2025 The Author(s). Aggregate published by SCUT, AIEI, and John Wiley & Sons Australia, Ltd.